A phase II trial of Lu radiolabeled monoclonal antibody HuJ591-GS (Lu-J591) [MLN 591RL] in patients with metastatic androgen-independent prostate cancer

Trial Profile

A phase II trial of Lu radiolabeled monoclonal antibody HuJ591-GS (Lu-J591) [MLN 591RL] in patients with metastatic androgen-independent prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 21 May 2013

At a glance

  • Drugs ATL 101 Telix Pharmaceuticals (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 04 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top